| Literature DB >> 34104272 |
Julie Hui-Chih Wu1, Fatima Khalid2, Bradley J Langford1, Nathan P Beahm3, Mark McIntyre4, Kevin L Schwartz1, Gary Garber1, Valerie Leung1.
Abstract
BACKGROUND: Pharmacist prescribing authority is expanding, while antimicrobial resistance is an increasing global concern. We sought to synthesize the evidence for antimicrobial prescribing by community pharmacists to identify opportunities to advance antimicrobial stewardship in this setting.Entities:
Year: 2021 PMID: 34104272 PMCID: PMC8165883 DOI: 10.1177/1715163521999417
Source DB: PubMed Journal: Can Pharm J (Ott) ISSN: 1715-1635
Overview of studies evaluating pharmacist prescribing of antimicrobial agents
| First author and year | Research objective | Country and sample size | Study design | Research theme | Included conditions | Key findings/results |
|---|---|---|---|---|---|---|
| Beahm | To evaluate effectiveness, safety of and patient satisfaction with pharmacist management of patients with uncomplicated UTI. | Canada | Nonrandomized controlled trial | Effectiveness | Uncomplicated UTI | Clinical cure was achieved in 88.9% of patients, similar to historical rates reported in the literature ( |
| Booth | To compare care of patients with UTI symptoms receiving GP services with those managed by community pharmacists. | United Kingdom | Nonrandomized controlled trial | Effectiveness | Uncomplicated UTI | Prescriptions were dispensed for 63% of patients receiving GP services for UTI. Of those managed by pharmacists, 27% received trimethoprim via PGD. There was no significant difference in time to symptom resolution between patients managed by a pharmacist and those receiving a physician prescription ( |
| Courtenay 2017[ | To describe patterns of dispensed prescriptions for antibiotics from prescribers other than physicians in primary care across England from 2011 to 2015. | United Kingdom | Observational; retrospective analysis, national prescribing database | Antimicrobial prescribing rate/utilization | No restriction | The rate and percentage of dispensed antibiotics prescribed by providers other than physicians increased over time; 1.2% of pharmacist prescriptions were for antibiotics. |
| Gauld | To assess impact of pharmacist supply of trimethoprim to women with uncomplicated cystitis on overall antibiotic use. | New Zealand | Before-after uncontrolled | Effectiveness | Uncomplicated UTI | Trimethoprim was the most commonly prescribed antibiotic in women with uncomplicated cystitis before and after policy implementation. Overall antibiotic use and use of second-line agents did not increase postimplementation. |
| Habicht | To examine differences in legislation, remuneration, uptake, continuing education requirements and resources for pharmacist prescribing for ambulatory ailments. | Canada | Environmental scan | Implementation/adoption | Cold sores, | Training requirements to prescribe for ambulatory ailments are inconsistent across provinces; pharmacist uptake of required training was 30% to 100%. Government funding for prescribing services is absent in most provinces. |
| Hall | To evaluate a community pharmacy consultation service for patients with ENT and eye conditions. | United Kingdom | Interventional study without comparison | Effectiveness | Acute otitis externa, acute otitis media, | Sixty-one percent of patients received a prescription-only medication as the result of consultation, mostly for sore throat (45%) and acute otitis media (32%). For sore throat, 83% received phenoxymethylpenicillin; for otitis media, 84% received amoxicillin. Patient satisfaction was high. |
| Hind | To evaluate the pilot and implementation of a community pharmacist-led service to manage uncomplicated UTI. | United Kingdom | Interventional study without comparison | Implementation/adoption | Uncomplicated UTI | In the pilot, 87.1% of patients received trimethoprim for treatment of uncomplicated UTI, with 90% of patients being seen in less than 10 minutes. Patients were highly satisfied with the service. During scale-up, pharmacists supplied 72.6% of patients with trimethoprim, which was found to be highly appropriate. The rate of retreatment (5.3%) was lower than that reported from historical local audits of physician prescriptions. |
| Klepser 2012[ | To evaluate cost-effectiveness of a community pharmacist program for management of pharyngitis caused by GAS vs standard of care. | United States | Economic analysis | Cost savings | Acute pharyngitis | Treatment of GAS pharyngitis by a pharmacist was the most cost-effective treatment strategy. The ICER for physician culture and was $6042 per QALD gained and $40,745 for physician RADT with follow-up culture. |
| Mansell 2015[ | To evaluate symptom improvement in patients prescribed treatment for minor ailments by a pharmacist. | Canada | Observational; patient survey | Effectiveness | Allergic rhinitis, diaper dermatitis, cold sores, | Cold sores were the most common condition (34.4%); the condition significantly/completely improved in 80.8% of patients. |
| Papastergiou 2018[ | To evaluate the effects and feasibility of community pharmacist-directed GAS testing. | Canada | Interventional study without comparison | Effectiveness | Acute pharyngitis | Of the patients, 25.5% tested positive for GAS. The overall antibiotic prescribing rate was 26%: 73.4% for those testing positive and 10.4% for those testing negative. Of those testing positive, 68.7% received same-day antibiotics. There was a higher rate of same-day prescriptions in Alberta for patients testing positive due to pharmacists having advanced prescribing authority compared with other provinces (73.8% vs 40.5%, |
| Rafferty | To conduct an economic impact analysis of the PPMA program in Saskatchewan. | Canada | Economic analysis | Cost savings | Acne, allergic rhinitis, athlete’s foot, canker sores, cold sores, | In 2014, the PPMA program saved $546,832 from a societal perspective and was marginally cost saving from the public payer perspective. After 5 years of implementation, from a societal perspective, cumulative cost savings were projected to be $3,482,660, and the return-on-investment ratio was estimated to be 2.53. |
| Stewart | To evaluate a service to improve access to treatment for uncomplicated UTI, impetigo and COPD exacerbation. | United Kingdom | Interventional study without comparison | Implementation/adoption | Impetigo, COPD exacerbation, | Overall, 77.9% of cases were prescribed medication by the pharmacist. Most cases were UTIs (75.4%); 76% were prescribed medication. Patients were satisfied with the service. Program cost for the service over the 5-month period was £29,615. |
| Thornley 2016[ | To evaluate a community pharmacy service incorporating RADT for patients with sore throat. | United Kingdom | Interventional study without comparison | Effectiveness | Acute pharyngitis | Of the 40.6% of patients eligible for testing, 24.2% were positive for GAS. Antibiotics were supplied to all patients who tested positive (9.8% of all patients). Potential cost of physician consultations avoided over the 7-month period was £2747. |
| Taylor 2017[ | To evaluate clinical outcomes in those receiving pharmacist-led care for 17 minor ailment conditions in Saskatchewan. | Canada | Observational; patient survey | Effectiveness | Acne, allergic rhinitis, athlete’s foot, canker sores, cold sores, | Almost all patients experienced symptom improvement following prescribing encounter. Patient satisfaction with the service was high. In the absence of the service, 30.6% of patients would have gone to a medical clinic or emergency room. |
COPD, chronic obstructive pulmonary disease; ENT, ear, nose and throat; GAS, group A Streptococcus; GP, general practice; ICER, incremental cost-effectiveness ratio; PGD, patient group direction; PPMA, Pharmacist Prescribing for Minor Ailments; QALD, quality-adjusted life day; RADT, rapid antigen detection test; UTI, urinary tract infection.
Conditions for which pharmacists were able to prescribe systemic antimicrobials in the corresponding study.
Types of study outcomes reported
| Prescribing outcomes | Patient-centred outcomes | Economic outcomes | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| First author and year | Prescribing rate/AMU | Drug selection | Guideline concordance | Clinical cure/ improvement | Treatment failure | Health care utilization | ADE | Access to care | Patient satisfaction | Cost | Other |
| Beahm 2018[ | X | X | X | X | X | X | Adherence to therapy, pharmacist modification of physician prescriptions | ||||
| Booth 2013[ | X | X | X | X | X | X | |||||
| Courtenay 2017[ | X | X | |||||||||
| Gauld 2017[ | X | X | |||||||||
| Habicht 2017[ | Uptake of education/ training programs | ||||||||||
| Hall 2019[ | X | X | X | ||||||||
| Hind 2018[ | X | X | X | X | X | X | Rate/results of urine dipstick testing, # of service claims | ||||
| Klepser 2012[ | X | ||||||||||
| Mansell 2015[ | X | X | X | X | X | X | |||||
| Papastergiou 2018[ | X | X | X | X | % positive GAS test | ||||||
| Rafferty 2017[ | X | ||||||||||
| Stewart 2018[ | X | X | X | X | X | ||||||
| Thornley 2016[ | X | X | X | X | % positive GAS test | ||||||
| Taylor 2017[ | X | X | X | X | X | ||||||
ADE, adverse drug event; AMU, antimicrobial use; GAS, group A Streptococcus.
Outcomes related to antimicrobial resistance or Clostridium difficile infections were not reported by any studies.
Overview of antimicrobial stewardship strategies incorporated
| First author and year | Antimicrobial stewardship strategies incorporated |
|---|---|
| Beahm 2018[ | |
| Booth 2013[ | Not reported. |
| Courtenay 2017[ | |
| Gauld 2017[ | |
| Habicht 2017[ | Not reported. |
| Hall 2019[ | Not reported. |
| Hind 2018[ | |
| Klepser 2012[ | Not reported. |
| Mansell 2015[ | Not reported. |
| Papastergiou 2018[ | |
| Rafferty 2017[ | Not reported. |
| Stewart 2018[ | |
| Thornley 2016[ | |
| Taylor 2017[ | Not reported. |
COPD, chronic obstructive pulmonary disease; PGD, patient group direction; RADT, rapid antigen detection test; UTI, urinary tract infection.
Figure 1Mapping of outcomes from included studies to outcomes relevant to outpatient antimicrobial stewardship programs